Novo Nordisk's European shares fell 11%. The company stated that in trials, its CagriSema was less effective than Eli Lilly's Zepbound.

2026-02-23

Novo Nordisk's European shares fell 11%. The company stated that in trials, its CagriSema was less effective than Eli Lilly's Zepbound.

Other News
2026-02-23

[Former Bank of Japan Board Member Makoto Sakurai: Bank of Japan May Raise Rates in March if Yen Falls Again] Former Bank of Japan board member Makoto Sakurai stated that if the yen falls again before the expected Japan-US summit in March, the Bank o

2026-02-23

Key Economic Data and Events to Watch Today: Monday, February 23, 2026 ① 17:00 Germany February IFO Business Climate Index ② 21:00 Fed Governor Waller Speaks ③ 23:00 US December Factory Orders MoM ④ 23:30 US February Dallas Fed Business Activity